Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK3145095 |
Synonyms | |
Therapy Description |
GSK3145095 is a small molecule that inhibits RIPK1, resulting in decreased downstream signaling, and potentially leading to reduced recruitment of immunosuppressive cells in the tumor microenvironment and increased tumor cell death (PMID: 31223438). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK3145095 | GSK 3145095|GSK-3145095 | GSK3145095 is a small molecule that inhibits RIPK1, resulting in decreased downstream signaling, and potentially leading to reduced recruitment of immunosuppressive cells in the tumor microenvironment and increased tumor cell death (PMID: 31223438). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |